RxDoctor Payments Data

Laura Coster, MD

Infectious Disease · Wheat Ridge, CONPI 1780855247

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 50 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Viiv Healthcare Company at 48.7% of the total.

$1,071in general payments, 2019–2025

Across 50 payments — averaging $21.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$521
  • AbbVie$427
  • Gilead$90
  • Insmed, Inc.$19
  • Johnson & Johnson$13

What the payments were for

  • Food & beverage$1,071100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Viiv Healthcare Company27$521
AbbVie17$427
Gilead4$90
Insmed, Inc.1$19
Johnson & Johnson1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,071 in reported general payments places this provider in the 75th percentile of 146 infectious disease providers in Colorado.

See all infectious disease providers in Colorado

Medicare billing

Part B allowed, 2024
$58,649
Medicare patients
236
Services billed
24,488

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala82$405,192
GenvoyaElviteg/Cob/Emtri/Tenof Alafen25$92,779
TivicayDolutegravir Sodium30$72,614
TriumeqAbacavir/Dolutegravir/Lamivudi19$70,843
PrezcobixDarunavir/Cobicistat13$37,144
EdurantRilpivirine Hcl12$17,231
Daptomycin15$5,067
Meropenem12$2,065
Vancomycin Hcl21$1,484
Doxycycline Monohydrate16$1,125
Cefadroxil27$980
Cefazolin Sodium12$766
Doxycycline Hyclate22$730
Fluconazole38$650
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav36$576

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya$90$497,972107 claims
Viiv Healthcare CompanyTivicay, Triumeq$521$143,45749 claims
Johnson & JohnsonPrezcobix$13$37,14413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 146 infectious disease providers in Colorado.

Other infectious disease in Wheat Ridge

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →